Search results for "hepatic"

showing 10 items of 609 documents

Lack of molluscan host diversity and the transmission of an emerging parasitic disease in Bolivia.

2001

Fasciolosis is a re-emerging parasitic disease that affects an increasing number of people in developing countries. The most severe endemic affects the Bolivian Altiplano, where the liver fluke (Fasciola hepatica) and its hermaphroditic snail host, Lymnaea truncatula, have been introduced from Europe. To achieve a better understanding of the epidemiological situation and the consequences of the colonization event of this invasive species, genetic analysis of Bolivian snail populations was needed. Here we compare the genetic diversity and population structure of snail samples from the Bolivian Altiplano with samples from the Old World at six polymorphic microsatellite loci. Whereas some vari…

0106 biological sciencesBoliviaOld WorldSnailsSnailBiology[Fasciola hepatica]010603 evolutionary biology01 natural sciencesHost-Parasite Interactions[microsatellites]03 medical and health sciencesbiology.animal[human disease]parasitic diseases[host–parasite interaction]GeneticsmedicineFasciola hepaticaAnimalsFasciolosisGenetic variabilityEcology Evolution Behavior and Systematics[Lymnaea truncatula]030304 developmental biology0303 health sciencesGenetic diversityHost (biology)Ecology[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]fungi15. Life on landmedicine.diseasebiology.organism_classificationEuropeGenetics PopulationParasitic disease[invasive species]Microsatellite RepeatsMolecular ecology
researchProduct

Occurrence of the LiverwortPallavicinia lyelliiin Poland

2018

Stebel, A., Fojcik, B., Rosadzinski, S. & Wierzcholska, S. 2018. Occurrence of the liverwort Pallavicinia lyellii in Poland. – Herzogia 31: 26–36.Pallavicinia lyellii, a liverwort species threatened in Europe, is a rare component of the bryoflora in Poland. This paper presents information on its 27 published and new sites, a brief discussion about ecology and threats, as well as a map of its current distribution in Poland.

0106 biological sciencesthreatened speciesCurrent distributionEcologyEcology (disciplines)010603 evolutionary biology01 natural scienceshepaticsGeographyThreatened speciesdistributionPallavicinia lyelliiecology010606 plant biology & botanyHerzogia
researchProduct

HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer

2021

Simple Summary It has been previously shown that activation of the MET receptor by its ligand, the hepatocyte growth factor (HGF), modulates the tumor-stroma cross-talk in models of pancreatic cancer. We now wish to cast light on the molecular mechanisms by which this ligand/receptor pair sustains the interaction between cancer cells and the tumor microenviroment. To this end, we compared data obtained by large-scale analysis of gene expression in pancreatic cancer cells grown in the presence of HGF versus cells grown in the presence of HGF and treated with specific inhibitors of HGF/MET signaling. By clustering differentially expressed genes according to functional groups, we identified ca…

0301 basic medicineCancer ResearchStromal cellpancreatic ductal adenocarcinomaArticle03 medical and health sciences0302 clinical medicinePancreatic tumorPancreatic cancerMET oncogenemedicinetumor microenvironmentmetastasisHepatocyte growth factor; MET oncogene; Metastasis; Pancreatic ductal adenocarcinoma; Tenascin C; Tumor microenvironmentRC254-282Tumor microenvironmentbiologyChemistryTenascin Ctenascin CNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyhepatocyte growth factorOncology030220 oncology & carcinogenesisCancer cellHepatic stellate cellbiology.proteinCancer researchHepatocyte growth factormedicine.drugCancers
researchProduct

Cytotoxic effects induced by patulin, deoxynivalenol and toxin T2 individually and in combination in hepatic cells (HepG2).

2018

Abstract Patulin (PAT), deoxynivalenol (DON) and toxin T-2 (T-2) are mycotoxins distributed worldwide in food and feed. Cytotoxicity of the three mycotoxins individually or in combination in human hepatocellular carcinoma (HepG2) cells was evaluated by MTT assay over 24, 48 and 72 h of exposure. The concentration ranges used were 0.625–15 μM for DON, 1.25–50 nM for T-2 and 0.45–7.5 μM for PAT. The IC 50 values obtained ranged from 9.30 to 2.53 μM, from 33.69 to 44.37 nM and from 2.66 to 1.17 μM for DON, T-2 and PAT, respectively. The most cytotoxic mycotoxin to HepG2 cells was T-2 followed by PAT and DON. The combination ratios used for the mixtures were 1:3 (DON: T-2), 1:5 (DON: PAT), 1:1.…

0301 basic medicineCell SurvivalComplex MixturesToxicologymedicine.disease_causePatulin03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500404 agricultural biotechnologymedicineCytotoxic T cellHumansMTT assayDrug InteractionsCytotoxicityMycotoxinDose-Response Relationship DrugToxin04 agricultural and veterinary sciencesGeneral MedicineHep G2 CellsMycotoxinsmedicine.disease040401 food scienceMolecular biologyDrug CombinationsT-2 Toxin030104 developmental biologyPatulinchemistryLiverHepatocellular carcinomaHepatic stellate cellTrichothecenesFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells

2017

AbstractWe have used a computational approach to identify anti-fibrotic therapies by querying a transcriptome. A transcriptome signature of activated hepatic stellate cells (HSCs), the primary collagen-secreting cell in liver, and queried against a transcriptomic database that quantifies changes in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap). The flavonoid apigenin was among 9 top-ranked compounds predicted to have anti-fibrotic activity; indeed, apigenin dose-dependently reduced collagen I in the human HSC line, TWNT-4. To identify proteins mediating apigenin’s effect, we next overlapped a 122-gene signature unique to HSCs with a list of 160 genes encoding…

0301 basic medicineCirrhosisCellPharmacologyBiologyArticleCell LineTranscriptome03 medical and health scienceschemistry.chemical_compoundMiceDrug DiscoverymedicineHepatic Stellate CellsAnimalsHumansApigeninMultidisciplinaryDrug Repositioningmedicine.diseaseHepatic stellate cell activationAntifibrinolytic Agents3. Good health030104 developmental biologymedicine.anatomical_structurechemistryCell cultureApigeninHepatic stellate cellHepatic fibrosisTranscriptomeBiomarkersScientific Reports
researchProduct

2018

Abstract Chronic hepatitis leads to liver fibrosis and cirrhosis. Cirrhosis is a major cause of worldwide morbidity and mortality. Macrophages play a key role in fibrosis progression and reversal. However, the signals that determine fibrogenic vs fibrolytic macrophage function remain ill defined. We studied the role of interleukin-4 receptor α (IL-4Rα), a potential central switch of macrophage polarization, in liver fibrosis progression and reversal. We demonstrate that inflammatory monocyte infiltration and liver fibrogenesis were suppressed in general IL-4Rα−/− as well as in macrophage-specific IL-4Rα−/− (IL-4RαΔLysM) mice. However, with deletion of IL-4RαΔLysM spontaneous fibrosis revers…

0301 basic medicineCirrhosisbusiness.industryMacrophage polarizationInflammationCCL4General MedicineCCL2medicine.diseaseGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences030104 developmental biologyFibrosisHepatic stellate cellCancer researchmedicineTumor necrosis factor alphamedicine.symptombusinessEBioMedicine
researchProduct

A Multi-Parametric Fluorescent Assay for the Screening and Mechanistic Study of Drug-Induced Steatosis in Liver Cells in Culture.

2017

Human hepatic cells have been used for drug safety risk evaluations throughout early development phases. They provide rapid, cost-effective early feedback to identify drug candidates with potential hepatotoxicity. This unit presents a cell-based assay to evaluate the risk of liver damage associated with steatogenic drugs. Detailed protocols for cell exposure to test compounds and for the assessment of steatosis-related cell parameters (intracellular lipid content, reactive oxygen species production, mitochondrial impairment, and cell death) are provided. A few representative results that illustrate the utility of this procedure for the screening of drug-induced steatosis are shown. © 2017 b…

0301 basic medicineDrugProgrammed cell deathmedia_common.quotation_subjectCellMitochondria LiverBiologyToxicology03 medical and health sciencesmedicineHumansCells Culturedmedia_commonchemistry.chemical_classificationReactive oxygen speciesCell Deathmedicine.diseaseLipid MetabolismFatty Liver030104 developmental biologymedicine.anatomical_structurechemistryBiochemistryLiverHigh-content screeningCancer researchHepatic stellate cellHepatocytesSteatosisChemical and Drug Induced Liver InjuryReactive Oxygen SpeciesIntracellularCurrent protocols in toxicologyLiterature Cited
researchProduct

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC …

2019

Drug-induced liver injury (DILI) is a matter of concern in the course of drug development and patient safety, often leading to discontinuation of drug-development programs or early withdrawal of drugs from market. Hepatocellular toxicity or impairment of bile acid (BA) metabolism, known as cholestasis, are the two clinical forms of DILI. Whole-body physiology-based modelling allows a mechanistic investigation of the physiological processes leading to cholestasis in man. Objectives of the present study were: (1) the development of a physiology-based model of the human BA metabolism, (2) population-based model validation and characterisation, and (3) the prediction and quantification of alter…

0301 basic medicineEXPRESSIONPBPKLIVERmedicine.drug_classPhysiologyBenign Recurrent Intrahepatic CholestasisPopulationBIOMARKERScomputational modellingPhysiologyDIAGNOSISlcsh:Physiology03 medical and health scienceschemistry.chemical_compoundPHARMACOKINETIC MODEL0302 clinical medicineCholestasisPhysiology (medical)Glycochenodeoxycholic acidMedicineddc:610educationEnterohepatic circulationKINETICSOriginal ResearchLiver injuryINTRAHEPATIC CHOLESTASISbile acidseducation.field_of_studyBile acidlcsh:QP1-981business.industryBRIC type 2medicine.diseaseTRANSPORTERS3. Good health030104 developmental biologychemistryToxicitySIMULATION030211 gastroenterology & hepatologyENTEROHEPATIC CIRCULATIONDILIbusinesscholestasisFrontiers in Physiology
researchProduct

Hyperalphalipoproteinemia and Beyond: The Role of HDL in Cardiovascular Diseases

2021

Hyperalphalipoproteinemia (HALP) is a lipid disorder characterized by elevated plasma high-density lipoprotein cholesterol (HDL-C) levels above the 90th percentile of the distribution of HDL-C values in the general population. Secondary non-genetic factors such as drugs, pregnancy, alcohol intake, and liver diseases might induce HDL increases. Primary forms of HALP are caused by mutations in the genes coding for cholesteryl ester transfer protein (CETP), hepatic lipase (HL), apolipoprotein C-III (apo C-III), scavenger receptor class B type I (SR-BI) and endothelial lipase (EL). However, in the last decades, genome-wide association studies (GWAS) have also suggested a polygenic inheritance o…

0301 basic medicineEndothelial lipasemedicine.medical_specialtyApolipoprotein BHDLSciencePopulationGenome-wide association studyReview030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicinecardiovascular diseaseInternal medicineCholesterylester transfer proteinMendelian randomizationCETPMedicineScavenger receptoreducationEcology Evolution Behavior and Systematicseducation.field_of_studybiologybusiness.industryQPaleontology030104 developmental biologyEndocrinologySpace and Planetary Sciencebiology.proteinlipids (amino acids peptides and proteins)Hepatic lipasehyperalphalipoproteinemiabusinesspolymorphisms
researchProduct

Higher physiopathogenicity byFasciola giganticathan by the genetically closeF. hepatica: experimental long-term follow-up of biochemical markers

2016

Background: Fascioliasis is caused by Fasciola hepatica and F. gigantica. The latter, always considered secondary in human infection, nowadays appears increasingly involved in Africa and Asia. Unfortunately, little is known about its pathogenicity, mainly due to difficulties in assessing the moment a patient first becomes infected and the differential diagnosis with F. hepatica. Methods: A long-term, 24-week, experimental study comparing F. hepatica and F. giganticawas made for the first time in the same animal model host, Guirra sheep. Serum biochemical parameters of liver damage, serum electrolytes, protein metabolism, plasma proteins, carbohydrate metabolism, hepatic lipid metabolism and…

0301 basic medicineFascioliasisMitochondrial DNAFasciola gigantica030231 tropical medicineAntibodies HelminthProtein metabolismSheep DiseasesPhysiologyCarbohydrate metabolismDiagnosis Differential03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSpecies SpecificityHepaticaparasitic diseasesAnimalsFasciola hepaticaBiochemical markersSheepbiologyPublic Health Environmental and Occupational HealthGeneral MedicineDNA Helminth030108 mycology & parasitologybiology.organism_classificationBlood proteinsFasciolaDisease Models AnimalInfectious DiseaseschemistryImmunoglobulin GParasitologyBiomarkersTransactions of The Royal Society of Tropical Medicine and Hygiene
researchProduct